Stage III Melanoma [clinicaltrials_resource:9bc16a0debe55c3cb0402ac6a49f6d4e]
Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma [clinicaltrials:NCT00003646]Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma [clinicaltrials:NCT00003647]Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg [clinicaltrials:NCT00003789]Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma [clinicaltrials:NCT00019890]Decitabine in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00030615]Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers [clinicaltrials:NCT00074308]Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma [clinicaltrials:NCT00082875]Tanespimycin in Treating Patients With Stage III-IV Melanoma [clinicaltrials:NCT00087386]Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors [clinicaltrials:NCT00089362]Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery [clinicaltrials:NCT00119249]Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery [clinicaltrials:NCT00217542]Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma [clinicaltrials:NCT00349206]clinicaltrials:NCT00450255clinicaltrials:NCT00945269Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma [clinicaltrials:NCT01026051]clinicaltrials:NCT01107665clinicaltrials:NCT01134614Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. [clinicaltrials:NCT01168050]clinicaltrials:NCT01726738clinicaltrials:NCT01851408clinicaltrials:NCT01875653Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma [clinicaltrials:NCT02073123]clinicaltrials:NCT02306850
condition [clinicaltrials_vocabulary:condition]
Stage III Melanoma [clinicaltrials_resource:9bc16a0debe55c3cb0402ac6a49f6d4e]
Bio2RDF identifier
9bc16a0debe55c3cb0402ac6a49f6d4e
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:9bc16a0debe55c3cb0402ac6a49f6d4e
identifier
clinicaltrials_resource:9bc16a0debe55c3cb0402ac6a49f6d4e
title
Stage III Melanoma
@en
label
Stage III Melanoma [clinicaltrials_resource:9bc16a0debe55c3cb0402ac6a49f6d4e]
@en